Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Virax Biolabs (US:VRAX) Prnewswire·2025-12-04 21:05

Accessibility StatementSkip Navigation Extends cash runway into first half of 2028, beyond planned completion of ViraxImmuneâ"¢Â US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships. LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nas ...